Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y

Pain, Stéphanie; Vergote, Jackie; Gulhan, Zuhal; Bodard, Sylvie; Chalon, Sylvie; Gaillard, Afsaneh

doi:10.1111/fcp.12464

Cited by 30 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NPY-regulated neurogenesis can be observed in the dentate gyrus, caudal subventricular zone (cSVZ), and subcallosal zone via the proliferative effect of Y1 receptors on neuroblasts [195]. Moreover, NYP administration protected neurons from microglia-caused inflammation in the striatum and substantia nigra of 6-OHDA-lesioned rats as a PD model [196]. Thus, NPY could be a potential therapeutic target for preventing neurodegeneration.…”

Section: Neuropeptides As a Target To Treat Neurodegenerationsmentioning

confidence: 99%

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam

Haque

Jakaria

et al. 2020

Cells

View full text Add to dashboard Cite

Neurodegenerative diseases are a large group of neurological disorders with diverse etiological and pathological phenomena. However, current therapeutics rely mostly on symptomatic relief while failing to target the underlying disease pathobiology. G-protein-coupled receptors (GPCRs) are one of the most frequently targeted receptors for developing novel therapeutics for central nervous system (CNS) disorders. Many currently available antipsychotic therapeutics also act as either antagonists or agonists of different GPCRs. Therefore, GPCR-based drug development is spreading widely to regulate neurodegeneration and associated cognitive deficits through the modulation of canonical and noncanonical signals. Here, GPCRs’ role in the pathophysiology of different neurodegenerative disease progressions and cognitive deficits has been highlighted, and an emphasis has been placed on the current pharmacological developments with GPCRs to provide an insight into a potential therapeutic target in the treatment of neurodegeneration.

show abstract

Section: Neuropeptides As a Target To Treat Neurodegenerationsmentioning

confidence: 99%

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam

Haque

Jakaria

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…NPY similarly inhibits microglial activation, phagocytosis, and cytokine secretion. It has been demonstrated that intracerebral injection of NPY (10 −2 g/L) can diminish microglial activation induced by 6-hydroxydopamine in rodents, and NPY inhibits microglial activation by binding to the translocator protein (TSPO) ligand [3H]PK11195 ( 84 ). Although NPY repressed microglial activity, it did not impair microglial survival.…”

Section: Npy Directly Regulates Immune Cellsmentioning

confidence: 99%

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Chen

Liu

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Neuropeptide Y (NPY), which is widely distributed in the nervous system, is involved in regulating a variety of biological processes, including food intake, energy metabolism, and emotional expression. However, emerging evidence points to NPY also as a critical transmitter between the nervous system and immune system, as well as a mediator produced and released by immune cells. In vivo and in vitro studies based on gene-editing techniques and specific NPY receptor agonists and antagonists have demonstrated that NPY is responsible for multifarious direct modulations on immune cells by acting on NPY receptors. Moreover, via the central or peripheral nervous system, NPY is closely connected to body temperature regulation, obesity development, glucose metabolism, and emotional expression, which are all immunomodulatory factors for the immune system. In this review, we focus on the direct role of NPY in immune cells and particularly discuss its indirect impact on the immune response.

show abstract

“…* P <0.05, ** P <0.01. ), which was considered to be a brain neuroprotective mechanism [ 39 ]. Although EA stimulation did not significantly increase NPY level in serum, it promoted this protective effect by remarkably enhancing NPY protein expression in PD model rats ( Figs.…”

Section: Resultsmentioning

confidence: 99%

Electroacupuncture alleviates Parkinson disease and regulates the expression of brain-gut peptides

Min

et al. 2020

Exp. Anim.

View full text Add to dashboard Cite

The non-motor symptoms (NMS) of Parkinson’s disease (PD) are found in more than 90% of patients with PD. Here, we explored the effects of electroacupuncture (EA) stimulation at Zhong wan (CV-12), Qihai (RN-7), Zusanli (ST-36) and Taichong (LR-3) on NMS and brain-gut peptides of PD. We found that EA intervention alleviated the motor deficit induced by 6-OHDA in rats indicated by the decreased abnormal involuntary movements (AIMs) scores and the net number of rotations and increased cylinder test grade. It also improved the spatial memory and attenuated anxiety-like and depression of PD model rats. EA treatment significantly inhibited neuronal apoptosis in PD model animals, as demonstrated by the increased number of TH positive cells and reduced number of apoptotic cells in the substantia nigra. The expression of cleaved caspase-3 and cleaved PARP in PD model rats was markedly suppressed by EA stimulation. Moreover, EA remarkably inhibited the inflammatory response in PD model rats, as revealed by the decreased levels of TNF-α, IL-1β, and COX-2 mRNA expression. It also attenuated the oxidative stress in rats, as indicated by the increased levels of SOD and GSH and the decreased level of MDA. EA treatment contributed to alleviating PD by regulating brain-gut peptides in rats, such as NPY, CCK, SST, GAS, and PYY. In conclusion, EA stimulation at CV-12, RN-7, ST-36, and LR-3 effectively alleviates the NMS of PD partly through regulating the levels of brain-gut peptides.

show abstract

Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y

Cited by 30 publications

References 35 publications

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Electroacupuncture alleviates Parkinson disease and regulates the expression of brain-gut peptides

Contact Info

Product

Resources

About